Free Trial
NASDAQ:RANI

Rani Therapeutics Q1 2026 Earnings Results & Report

Rani Therapeutics logo
$0.53 +0.00 (+0.21%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$0.52 -0.01 (-1.58%)
As of 11/13/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rani Therapeutics beat analyst expectations on both earnings and revenue in its Q1 2026 results, released May 15, 2026. The company reported EPS of -$0.04 versus the -$0.06 consensus estimate, while revenue of $1.71 million topped the $1.13 million estimate by $583 thousand.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Rani Therapeutics EPS Results

Actual EPS
-$0.04
Consensus EPS
-$0.06
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Rani Therapeutics Revenue Results

Actual Revenue
$1.71 million
Expected Revenue
$1.13 million
Beat/Miss
Beat by +$583.00 thousand
YoY Revenue Growth
N/A

Rani Therapeutics Q1 2026 Earnings FAQ

Rani Therapeutics (NASDAQ:RANI) reported earnings of -$0.04 per share for Q1 2026, beating the consensus estimate of -$0.06. The report was announced on Friday, May 15, 2026.

Rani Therapeutics reported revenue of $1.71 million for Q1 2026, against a consensus estimate of $1.13 million.

Rani Therapeutics Earnings Headlines

I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
Rani Therapeutics (RANI) Expected to Release Earnings on Thursday
See More Rani Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rani Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rani Therapeutics and other key companies, straight to your email.

About Rani Therapeutics

Rani Therapeutics (NASDAQ:RANI) is a clinical-stage biotherapeutics company developing technology to deliver biologic medicines orally. Its RaniPill platform is designed to transport drugs such as peptides and antibodies through the digestive system and release them into the intestinal wall, with the goal of offering an alternative to injections.

Founded in 2012 and based in San Jose, California, the company develops its delivery platform and evaluates it with drug candidates and potential partner medicines. Rani’s work focuses on addressing challenges that have traditionally made many biologic drugs difficult to administer by mouth.

View Rani Therapeutics Profile